A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 268 participants.
Also called NCT02794792
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 268 participants
- Sponsor
- Registry
-
NCT02794792
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT02794792. Randomized; triple masking; primary purpose treatment. Start 2016-05-11 (actual); primary completion 2017-03-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
- Acronym
- IMPRESSION
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ipragliflozin L-proline
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Astellas Pharma Europe B.V.
Record details
- Record id
cardio:ct-nct02794792- Content hash
7b33123a085e8ff092bec354b2739a94f17cac7ce5b51a0150fb42bbdda394bd